当前位置:首页 - 行情中心 - 瑞普生物(300119) - 财务分析 - 利润表

瑞普生物

(300119)

  

流通市值:46.39亿  总市值:64.72亿
流通股本:3.34亿   总股本:4.66亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入1,587,164,776.49994,096,256.27442,780,482.142,084,250,399
营业收入1,587,164,776.49994,096,256.27442,780,482.142,084,250,399
二、营业总成本1,314,397,482.78823,889,058.32361,812,573.711,731,931,439.69
营业成本778,537,880.9477,381,286.96217,072,435.661,074,613,111.23
税金及附加15,144,157.7810,239,808.253,685,790.1520,400,111.66
销售费用266,621,217.9176,385,967.3970,188,590.29344,074,235.79
管理费用115,568,835.7373,603,846.733,672,025.1142,818,602.93
研发费用124,183,791.0476,985,881.1532,060,179.48132,678,458.42
财务费用14,341,599.439,292,267.875,133,553.0317,346,919.66
其中:利息费用18,361,455.7612,312,317.496,350,329.9128,434,228.53
其中:利息收入4,132,674.482,943,375.841,521,081.1311,198,528.02
加:公允价值变动收益29,776,681.1321,961,740.0814,764,322.0551,383,158.22
加:投资收益23,602,091.2721,393,115.52-300,766.254,050,892.34
资产处置收益137,384.9976,697.88--6,985.41
资产减值损失(新)934,206.98772,146.88541,387.14473,470.3
信用减值损失(新)-21,454,014.5-9,118,488.96-4,624,161.86-18,744,013.75
其他收益20,954,764.3310,597,858.947,185,565.727,162,946.71
营业利润平衡项目0000
四、营业利润326,718,407.91215,890,268.2998,534,255.21416,638,427.72
加:营业外收入489,384.84115,513.82107,224.563,423,695.49
减:营业外支出1,122,261.11899,433.43458,148.066,250,730.23
利润总额平衡项目0000
五、利润总额326,085,531.64215,106,348.6898,183,331.71413,811,392.98
减:所得税费用31,184,567.6821,632,435.6810,680,506.0940,041,535.02
六、净利润294,900,963.96193,473,91387,502,825.62373,769,857.96
持续经营净利润294,900,963.96193,473,91387,502,825.62373,769,857.96
归属于母公司股东的净利润273,697,993.12178,271,133.7480,823,461.46346,698,684.97
少数股东损益21,202,970.8415,202,779.266,679,364.1627,071,172.99
(一)基本每股收益0.590.380.170.75
(二)稀释每股收益0.590.380.170.75
九、综合收益总额294,900,963.96193,473,91387,502,825.62373,769,857.96
归属于母公司股东的综合收益总额273,697,993.12178,271,133.7480,823,461.46346,698,684.97
归属于少数股东的综合收益总额21,202,970.8415,202,779.266,679,364.1627,071,172.99
公告日期2023-10-262023-08-262023-04-272023-04-01
审计意见(境内)标准无保留意见
TOP↑